Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03670810 · ClinicalTrials.gov registry record · Phase 3
A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
A Phase 3 study of Migraine, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,633
- Enrollment target
- 20
- Study locations
NCT03670810: Completed Phase 3 study of Migraine, sponsored by Eli Lilly and Company.
NCT03670810 is a Phase 3 study of Migraine that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,633 participants, above the 342-participant average among 102 other Migraine trials with a reported enrollment target (377% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03670810, a Phase 3 study of Migraine, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,633 participants
- Enrollment target
- 20
- Study locations
Study Summary
The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.
Primary Outcome
Pain-free is defined as mild, moderate, or severe headache pain becoming none at 2 hours postdose during the first attack.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lasmiditan
Study Locations (20)
New York
- Dent Neurological Institute - Amherst
- Island Neuro Associates,PC - Plainview
- Montefiore Headache Center - The Bronx
Other
- Christian-Doppler-Klinik - Salzburg
- AKH - Vienna
- Algemeen Ziekenhuis St Jan Brugge - Bruges
District of Columbia
- Georgetown University Hospital - Washington D.C.
- George Washington University Medical Center - Washington D.C.
Alabama
- Rehabilitation & Neurological Services LLC - Huntsville
Arizona
- Barrow Neurological Institute - Phoenix
California
- UCSD Altman Clinical & Translational Research Institute (ACTRI) - La Jolla
Colorado
- Colorado Neurological Institute - Englewood
Illinois
- Diamond Headache Clinic - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,633 participants |
| Start Date | 2019-06-24 |
| Est. Completion | 2021-07-08 |
| Phase | Phase 3 |
What the finished NCT03670810 record still lists
NCT03670810 is an interventional study that assigns participants to a tested intervention. Its 1,633 participants enrollment target places it among the larger protocols in the corpus, above the 342-participant average among 102 other Migraine trials with a reported enrollment target (377% higher).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03670810 names 20 study sites across 15 states, led by New York, Other, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT03670810 about?
NCT03670810 is a clinical study titled "A Study of Lasmiditan (LY573144) Over Four Migraine Attacks". The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.
What is the current status of trial NCT03670810?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,633 participants. The study started on 2019-06-24. Estimated completion is 2021-07-08.
What conditions does trial NCT03670810 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT03670810?
The interventions under investigation include: Placebo (DRUG), Lasmiditan (DRUG).
Who is sponsoring clinical trial NCT03670810?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03670810 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03670810's enrollment target sits among peer trials
1,633 6th of 102 higher than 97 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04510129 · 1,650 participants
A Multicenter Cancer Biospecimen Collection Study
- NCT05612750 · 1,650 participants · NA
Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study
- NCT06215716 · 1,650 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- NCT07046260 · 1,650 participants
Prospective Study to Assess a Diagnostic Aid for Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI